Cómo contactar con el centro
Centro HCP
Entregando alta calidad verificable
Ofreciendo atención sanitaria participativa y personalizada.
Utilizar nuestros recursos de manera eficiente
Participar en redes profesionales sostenibles en todos los ámbitos.
El departamento de Oftalmología de Radboudumc es un centro terciario de primer nivel para diversas enfermedades oculares y es un experto líder en el tratamiento y manejo de enfermedades de la retina. Además de la atención clínica diaria, investigamos enfermedades de la retina. Los principales objetivos de nuestra investigación son comprender mejor las bases moleculares de estas enfermedades y desarrollar nuevos dispositivos de diagnóstico y terapias.
El departamento de Genética Humana de Radboudumc lleva a cabo investigaciones innovadoras sobre la relación entre genes y enfermedades. La atención al paciente (división de genética clínica) y el diagnóstico genético (división de diagnóstico del genoma) realizados dentro del departamento de Genética Humana están a cargo de un Centro de Genética Clínica oficial y aclamado.
Foto : .Koen
Contacto
Radboud university medical center, Nijmegen, Netherlands
Equipo
Pr Carel HOYNG
Países Bajos
Pr Frans Cremers
Países Bajos
Los ensayos clínicos
NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients With Retinitis Pigmentosa
A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate and Early Atrophic AMD Cases to Study Prediction of Disease Progression: (INTERCEPT-AMD)
Steroid Eye Drops Versus Placebo Eye Drops in Chronic Central Serous Chorioretinopathy Trial (PICS Trial)
Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
Rate of Progression in EYS Related Retinal Degeneration (Pro-EYS).
A double-masked, randomized, controlled, multiple-dose study to evaluate the efficacy, safety, tolerability and systemic exposure of QR-110 in Subjects with Leber’s Congenital Amaurosis (LCA) due to c.2991+1655A>G mutation (p.Cys998X) in the CEP290 gene (Illuminate).
Safety and Efficacy of Emixustat in Stargardt Disease.
Natural History of the Progression of Choroideremia Study NSR-CHM-OS1.
Rate of Progression in USH2A Related Retinal Degeneration
A Long-term Follow-up Study to Evaluate the Safety and efficacy of Retinal Gene Therapy in Subjects with choroideremia treated previously with Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) in an Antecedent Study.
Half-dose photodynamic therapy versus eplerenone treatment in chronic centralserous chorioretinopathy.
A Non-interventional Study of Clinical Experience in Patients Prescribed Raxone® for the Treatment of Leber’s Hereditary Optic Neuropathy (LHON).
A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Rate of Progression of PCDH15-Related Retinal Degeneration in Usher
Natural history of the progression of X-linked retinitis pigmentosa.